share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  05/23 13:18
Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.
Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.
处于开发阶段的企业Alterity Therapeutics Limited报告称，由于有条件权利的失效，已停止500万份期权。这些期权由澳大利亚证券交易所安全代码ATHAAE确定，将于2026年11月29日到期，行使价为0.0375美元，由于行使条件未得到满足或无法满足，于2024年5月7日终止。停职归因于员工辞职。此次活动之后，该公司的已发行资本包括超过52亿股全额支付的普通股以及具有不同到期日和行使价的各种期权。该公告于2024年5月21日发布，符合1934年《证券交易法》的规定，因为Alterity Therapeutics是一家在美国证券交易委员会注册的外国私人发行人。
处于开发阶段的企业Alterity Therapeutics Limited报告称，由于有条件权利的失效，已停止500万份期权。这些期权由澳大利亚证券交易所安全代码ATHAAE确定，将于2026年11月29日到期，行使价为0.0375美元，由于行使条件未得到满足或无法满足，于2024年5月7日终止。停职归因于员工辞职。此次活动之后，该公司的已发行资本包括超过52亿股全额支付的普通股以及具有不同到期日和行使价的各种期权。该公告于2024年5月21日发布，符合1934年《证券交易法》的规定，因为Alterity Therapeutics是一家在美国证券交易委员会注册的外国私人发行人。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息